One of the worlds deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.
Dr Anthony Sanchez, from the Centers for Disease Control & Prevention in Atlanta, Georgia is presenting an overview of Ebola vaccine development today (Monday 31 March 2008) at the Society for General Microbiologys 162nd meeting being held this week at the Edinburgh International Conference Centre.
The biothreat posed by Ebola virus cannot be overlooked. We are seeing more and more naturally occurring human outbreaks of this deadly disease. With worldwide air travel and tourism the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism, says Dr Sanchez. We desperately need a protective vaccine.
So far, there have been over 1500 cases of Ebola haemorrhagic fever in humans. Illness starts abruptly and symptoms include fever, headache, sore throat, weakness, joint and muscle aches, diarrhoea, vomiting and stomach pain. A rash, red eyes and bleeding may also occur. Ebola haemorrhagic fever can have a mortality rate of around 90% in humans.
Because Ebola virus is so dangerous, producing and testing a vaccine is extremely challenging for the scientists. One significant factor slowing down progress has been that there are only a very limited number of high containment facilities with staff capable and authorised to conduct the research.
Ebola virus is a Biosafety Level 4 threat, along with many other haemorrhagic fever viruses, says Dr Sanchez. As well as the difficulty in getting the right staff and facilities, vaccines for viruses like Ebola, Marburg and Lassa fever have been difficult to produce because simple killed viruses that just trigger an antibody response from the blood are not effective. For the
|Contact: Lucy Goodchild|
Society for General Microbiology